HRP20110219T1 - Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida - Google Patents

Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida Download PDF

Info

Publication number
HRP20110219T1
HRP20110219T1 HR20110219T HRP20110219T HRP20110219T1 HR P20110219 T1 HRP20110219 T1 HR P20110219T1 HR 20110219 T HR20110219 T HR 20110219T HR P20110219 T HRP20110219 T HR P20110219T HR P20110219 T1 HRP20110219 T1 HR P20110219T1
Authority
HR
Croatia
Prior art keywords
sulfonamido
inhibitor
amyloid peptide
beta amyloid
peptide production
Prior art date
Application number
HR20110219T
Other languages
English (en)
Croatian (hr)
Inventor
E. Starrett John Jr.
W. Gillman Kevin
E. Olson Richard
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110219(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20110219T1 publication Critical patent/HRP20110219T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20110219T 2007-10-31 2008-10-14 Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida HRP20110219T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
PCT/US2008/079798 WO2009058552A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
HRP20110219T1 true HRP20110219T1 (hr) 2011-04-30

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20110219T HRP20110219T1 (hr) 2007-10-31 2008-10-14 Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida
HRP20120703AT HRP20120703T1 (hr) 2007-10-31 2012-09-04 Novi intermedijeri korisni za pripremu alfa-(n-sulfonamido)acetamido spoja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120703AT HRP20120703T1 (hr) 2007-10-31 2012-09-04 Novi intermedijeri korisni za pripremu alfa-(n-sulfonamido)acetamido spoja

Country Status (28)

Country Link
US (2) US8084477B2 (enExample)
EP (3) EP2471769A1 (enExample)
JP (1) JP5460605B2 (enExample)
KR (1) KR20100075575A (enExample)
CN (2) CN101910141B (enExample)
AR (1) AR069135A1 (enExample)
AT (1) ATE502022T1 (enExample)
AU (1) AU2008319122A1 (enExample)
BR (1) BRPI0818837A2 (enExample)
CA (1) CA2704360A1 (enExample)
CL (1) CL2008003271A1 (enExample)
CO (1) CO6270332A2 (enExample)
CY (2) CY1112337T1 (enExample)
DE (1) DE602008005636D1 (enExample)
DK (2) DK2295417T3 (enExample)
EA (2) EA016447B1 (enExample)
ES (2) ES2361283T3 (enExample)
HR (2) HRP20110219T1 (enExample)
IL (1) IL205406A0 (enExample)
MX (1) MX2010004319A (enExample)
NZ (1) NZ584545A (enExample)
PE (1) PE20091394A1 (enExample)
PL (2) PL2295417T3 (enExample)
PT (2) PT2205575E (enExample)
SG (2) SG174044A1 (enExample)
SI (2) SI2295417T1 (enExample)
TW (1) TW200927099A (enExample)
WO (1) WO2009058552A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465861B1 (en) 2001-12-20 2009-05-06 Bristol-Myers Squibb Company Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
EP2408450B1 (en) * 2009-03-19 2013-03-13 Bristol-Myers Squibb Company Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
JP5627038B2 (ja) 2010-03-12 2014-11-19 日本曹達株式会社 ピリジン環含有化合物
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012069428A1 (en) * 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015534553A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換１，５−ベンゾジアゼピノン化合物
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
CZ291659B6 (cs) * 1995-11-17 2003-04-16 Warner-Lambert Company Sulfonamidové inhibitory matricových metaloproteináz
PL331338A1 (en) 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
HK1038915A1 (zh) 1999-01-27 2002-04-04 Wyeth Holdings Corporation 乙炔磺胺硫醇三对甲氧苯基氯乙烯(tace)抑制物
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
IL144781A0 (en) 1999-02-26 2002-06-30 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
DE60239078D1 (de) * 2001-12-14 2011-03-10 Raytheon Co Präzise justierte linsenstruktur und eine methode zur herstellung derselben
EP1465861B1 (en) * 2001-12-20 2009-05-06 Bristol-Myers Squibb Company Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
RU2004129278A (ru) * 2002-02-28 2005-06-10 Астразенека Аб (Se) Химические соединения
ATE362368T1 (de) * 2003-03-20 2007-06-15 Santhera Pharmaceuticals Ch Substituierte piperidin- und piperazin-derivative als melanocortin-4 receptor modulatoren
TWI336698B (en) * 2003-03-31 2011-02-01 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7144894B2 (en) * 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
RU2008129797A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Способы получения сульфонамид-замещенных спиртов и их промежуточных соединений
BRPI0707742A2 (pt) * 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
AU2008319122A1 (en) 2009-05-07
US20090111858A1 (en) 2009-04-30
JP2011502153A (ja) 2011-01-20
DE602008005636D1 (de) 2011-04-28
US8350084B2 (en) 2013-01-08
DK2295417T3 (da) 2012-10-15
MX2010004319A (es) 2010-04-30
PL2295417T3 (pl) 2012-11-30
CL2008003271A1 (es) 2009-07-10
NZ584545A (en) 2011-04-29
BRPI0818837A2 (pt) 2015-04-22
CO6270332A2 (es) 2011-04-20
US8084477B2 (en) 2011-12-27
EP2295417A1 (en) 2011-03-16
SG174044A1 (en) 2011-09-29
CY1113346T1 (el) 2016-06-22
US20120088925A1 (en) 2012-04-12
EA201171439A1 (ru) 2012-05-30
PT2205575E (pt) 2011-05-23
CY1112337T1 (el) 2015-12-09
EP2471769A1 (en) 2012-07-04
SG174043A1 (en) 2011-09-29
PT2295417E (pt) 2012-09-26
ATE502022T1 (de) 2011-04-15
JP5460605B2 (ja) 2014-04-02
EA201000714A1 (ru) 2010-10-29
SI2205575T1 (sl) 2011-07-29
CA2704360A1 (en) 2009-05-07
WO2009058552A1 (en) 2009-05-07
CN101910141A (zh) 2010-12-08
EP2295417B1 (en) 2012-07-04
ES2361283T3 (es) 2011-06-15
EP2205575A1 (en) 2010-07-14
PL2205575T3 (pl) 2011-09-30
EA016447B1 (ru) 2012-05-30
DK2205575T3 (da) 2011-07-11
KR20100075575A (ko) 2010-07-02
HRP20120703T1 (hr) 2012-09-30
TW200927099A (en) 2009-07-01
HK1155161A1 (en) 2012-05-11
CN102718689A (zh) 2012-10-10
EP2205575B1 (en) 2011-03-16
SI2295417T1 (sl) 2012-11-30
PE20091394A1 (es) 2009-09-25
AR069135A1 (es) 2009-12-30
ES2390042T3 (es) 2012-11-06
HK1141801A1 (en) 2010-11-19
IL205406A0 (en) 2010-12-30
CN101910141B (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
HRP20110219T1 (hr) Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
WO2007111904A3 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
CL2007002169A1 (es) Compuestos derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso del compuesto para prevenir o tratar la inflamacion, trastornos urologicos, gastrointestina
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
DK1933833T3 (da) Terapi til behandling af overaktiv blære
EP3276004A3 (en) Methods for treating chronic kidney disease
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
BRPI0517227B8 (pt) comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
TW200700392A (en) Novel compounds
ATE542814T1 (de) Pyrazinkinaseinhibitoren
CL2007002195A1 (es) Compuesto n-((1r,2s,5r)-5-(isopropil(metil)amino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales com
ATE502935T1 (de) C-met-proteinkinasehemmer
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
EA201171143A1 (ru) Новое соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продукции бета амилоидного пептида
JP2012520896A5 (enExample)
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.